Notice2022-03953
Foreign-Trade Zone (FTZ) 99-Wilmington, Delaware, Notification of Proposed Production Activity AstraZeneca Pharmaceuticals, LP (Pharmaceutical Products), Newark, Delaware
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
February 25, 2022
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 38 (Friday, February 25, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 38 (Friday, February 25, 2022)]
[Notices]
[Page 10771]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-03953]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-05-2022]
Foreign-Trade Zone (FTZ) 99--Wilmington, Delaware, Notification
of Proposed Production Activity AstraZeneca Pharmaceuticals, LP
(Pharmaceutical Products), Newark, Delaware
AstraZeneca Pharmaceuticals, LP submitted a notification of
proposed production activity to the FTZ Board (the Board) for its
facility in Newark, Delaware within Subzone 99D. The notification
conforming to the requirements of the Board's regulations (15 CFR
400.22) was received on February 16, 2022.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status materials and specific finished
products described in the submitted notification (summarized below) and
subsequently authorized by the Board. The benefits that may stem from
conducting production activity under FTZ procedures are explained in
the background section of the Board's website--accessible via
<a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>. The proposed finished products and materials would
be added to the production authority that the Board previously approved
for the operation, as reflected on the Board's website.
The proposed finished products include: BRILINTA (ticagrelor)
tablets; LYNPARZA (olaparib) tablets; SEROQUEL IR (quetiapine fumarate)
tablets; and, SEROQUEL XR (quetiapine fumarate) tablets (duty-free).
The proposed foreign-status materials include: Anastrozole active
pharmaceutical ingredient (API); olaparib API; quetiapine fumarate API;
and, ticagrelor API (duty rates 6.5%). The request indicates that
olaparib API and ticagrelor API are subject to duties under Section 301
of the Trade Act of 1974 (Section 301), depending on the country of
origin. The applicable Section 301 decisions require subject
merchandise to be admitted to FTZs in privileged foreign status (19 CFR
146.41).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#7e180a043e0a0c1f1a1b50191108"><span class="__cf_email__" data-cfemail="6701131d27131506030249000811">[email protected]</span></a>. The closing period for their receipt is April 6, 2022.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Christopher Wedderburn at
<a href="/cdn-cgi/l/email-protection#0f4c677d667c21586a6b6b6a7d6d7a7d614f7b7d6e6b6a21686079"><span class="__cf_email__" data-cfemail="2063485249530e7745444445524255524e6054524144450e474f56">[email protected]</span></a>.
Dated: February 18, 2022.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2022-03953 Filed 2-24-22; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on February 25, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.